Darunavir-based single pill FDC approved in EU (Symtuza)
Simon Collins, HIV i-Base
On 27 September 2017, the first protease inhibitor-based fixed dose combination (FDC) was approved in Europe by the European Medicines Agency (EMA). 
The once-daily FDC combines darunavir 800 mg, cobicistat 150 mg and emtricitabine/tenofovir alafenamide 200 mg/10 mg fixed-dose combination (D/C/F/TAF).
The indication is for HIV positive adults and adolescents aged 12 years and older.
The combination needs to be taken once-daily with food. Approval is based on phase 3 studies showing bioequivalence to the individual components being taken separately.
This FDC is marketed by Janssen-Cilag with the brand name Symtuza.
For full details see the SPC and patient information on the EMA website. 
- Janssen press statement. European Commission approves Symtuza for the treatment of HIV-1 in adults and adolescents in Europe. (27 September 2017).
- European Summary of Product Charateristics (SPC) for Symtuza. (September 2017).